What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?

Protein convertase subtilisin –kexin type 9 (PCSK9) inhibitors effectively clear low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). We evaluated stroke admissions potentially eligible for more intensive cholesterol treatment.

Source: Journal of Stroke and Cerebrovascular Diseases - November 11, 2019 Category: Neurology Authors: Vafa Alakbarzade, Anthony C. Pereira Source Type: research